- Home
- BBNX vs GHRS Comparison
BBNX vs GHRS Comparison
Compare BBNX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBNX
- GHRS
- Stock Information
- Founded
- BBNX 2015
- GHRS 2018
- Country
- BBNX United States
- GHRS Ireland
- Employees
- BBNX N/A
- GHRS N/A
- Industry
- BBNX Medical/Dental Instruments
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- BBNX Health Care
- GHRS Health Care
- Exchange
- BBNX Nasdaq
- GHRS Nasdaq
- Market Cap
- BBNX 967.6M
- GHRS 774.1M
- IPO Year
- BBNX 2025
- GHRS 2021
- Fundamental
- Price
- BBNX $22.26
- GHRS $13.10
- Analyst Decision
- BBNX Strong Buy
- GHRS Strong Buy
- Analyst Count
- BBNX 10
- GHRS 8
- Target Price
- BBNX $26.10
- GHRS $30.63
- AVG Volume (30 Days)
- BBNX 1.2M
- GHRS 307.7K
- Earning Date
- BBNX 11-06-2025
- GHRS 11-13-2025
- Dividend Yield
- BBNX N/A
- GHRS N/A
- EPS Growth
- BBNX N/A
- GHRS N/A
- EPS
- BBNX N/A
- GHRS N/A
- Revenue
- BBNX $78,022,000.00
- GHRS N/A
- Revenue This Year
- BBNX $42.80
- GHRS N/A
- Revenue Next Year
- BBNX $34.58
- GHRS N/A
- P/E Ratio
- BBNX N/A
- GHRS N/A
- Revenue Growth
- BBNX 550.45
- GHRS N/A
- 52 Week Low
- BBNX $8.89
- GHRS $6.00
- 52 Week High
- BBNX $26.66
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- BBNX 56.75
- GHRS 45.98
- Support Level
- BBNX $19.07
- GHRS $13.00
- Resistance Level
- BBNX $21.08
- GHRS $14.96
- Average True Range (ATR)
- BBNX 1.44
- GHRS 0.78
- MACD
- BBNX -0.45
- GHRS -0.00
- Stochastic Oscillator
- BBNX 52.15
- GHRS 28.46
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.